Raffaele Di Francia

Summary

Publications

  1. ncbi request reprint Evaluation of genotyping methods and the relative cost of pharmacogenomics
    A De Monaco
    Laboratory of Molecular Haematology, National Cancer Institute, Fondazione G Pascale IRCCS, Naples, Italy
    Eur Rev Med Pharmacol Sci 18:2084-7. 2014
  2. doi request reprint Molecular diagnostics for pharmacogenomic testing of fluoropyrimidine based-therapy: costs, methods and applications
    Raffaele Di Francia
    Laboratory of Molecular Haematology, National Cancer Institute, Fondazione G Pascale IRCCS, Naples, Italy
    Clin Chem Lab Med 49:1105-11. 2011
  3. ncbi request reprint Promestriene, a specific topic estrogen. Review of 40 years of vaginal atrophy treatment: is it safe even in cancer patients?
    Lino Del Pup
    Departments of aGynecological Oncology bMedical Oncology cScientific Direction, National Cancer Institute, Aviano PN dHematology Oncology and Stem Cell transplantation Unit eDepartment of Uro Gynecological Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione Giovanni Pascale IRCCS, Naples, Italy
    Anticancer Drugs 24:989-98. 2013
  4. ncbi request reprint Current strategies to minimize toxicity of oxaliplatin: selection of pharmacogenomic panel tests
    Raffaele Di Francia
    aHematology Oncology and Stem Cell Transplantation Unit bUro Gynaecologic Department cAbdominal Department, Medical Oncology Unit, National Cancer Institute, Fondazione G Pascale IRCCS dItalian Association of Pharmacogenomics and Molecular Diagnostics eMMG ASL CE1, Medicina del Lavoro fCETAC Research Center, Caserta gDepartment of Medical Oncology, CRO National Cancer Institute, Aviano PN, Italy
    Anticancer Drugs 24:1069-78. 2013
  5. pmc Expression of the brain transcription factor OTX1 occurs in a subset of normal germinal-center B cells and in aggressive Non-Hodgkin Lymphoma
    Daniela Omodei
    Centro di Ingegneria Genetica CEINGE Biotecnologie Avanzate, Naples, Italy
    Am J Pathol 175:2609-17. 2009
  6. doi request reprint Decision criteria for rational selection of homogeneous genotyping platforms for pharmacogenomics testing in clinical diagnostics
    Raffaele Di Francia
    Hematology Oncology and Stem Cell Transplantation Unit, National Cancer Institute, Fondazione G Pascale IRCCS, Naples, Italy
    Clin Chem Lab Med 48:447-59. 2010
  7. ncbi request reprint Nutrition in oncologic patients during antiblastic treatment
    Massimiliano Berretta
    Department of Medical Oncology, Centro di Riferimento Oncologico, National Cancer Institute, Aviano, Via Franco Gallini 2, 33081 Aviano PN, Italy
    Front Biosci (Landmark Ed) 18:120-32. 2013

Collaborators

Detail Information

Publications7

  1. ncbi request reprint Evaluation of genotyping methods and the relative cost of pharmacogenomics
    A De Monaco
    Laboratory of Molecular Haematology, National Cancer Institute, Fondazione G Pascale IRCCS, Naples, Italy
    Eur Rev Med Pharmacol Sci 18:2084-7. 2014
    ..Finally, with the progress made in this scenario over the next five years, health decision-making may able to accelerating the translation of genetic technologies into routine clinical laboratory. ..
  2. doi request reprint Molecular diagnostics for pharmacogenomic testing of fluoropyrimidine based-therapy: costs, methods and applications
    Raffaele Di Francia
    Laboratory of Molecular Haematology, National Cancer Institute, Fondazione G Pascale IRCCS, Naples, Italy
    Clin Chem Lab Med 49:1105-11. 2011
    ..00 per single polimorphism. On the basis of this information, the lab manager can evaluate the advantage and limitations, in terms of costs and applicability, of the most appropriate methods for diagnostics of 5-FU pharmacogenomics tests...
  3. ncbi request reprint Promestriene, a specific topic estrogen. Review of 40 years of vaginal atrophy treatment: is it safe even in cancer patients?
    Lino Del Pup
    Departments of aGynecological Oncology bMedical Oncology cScientific Direction, National Cancer Institute, Aviano PN dHematology Oncology and Stem Cell transplantation Unit eDepartment of Uro Gynecological Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione Giovanni Pascale IRCCS, Naples, Italy
    Anticancer Drugs 24:989-98. 2013
    ....
  4. ncbi request reprint Current strategies to minimize toxicity of oxaliplatin: selection of pharmacogenomic panel tests
    Raffaele Di Francia
    aHematology Oncology and Stem Cell Transplantation Unit bUro Gynaecologic Department cAbdominal Department, Medical Oncology Unit, National Cancer Institute, Fondazione G Pascale IRCCS dItalian Association of Pharmacogenomics and Molecular Diagnostics eMMG ASL CE1, Medicina del Lavoro fCETAC Research Center, Caserta gDepartment of Medical Oncology, CRO National Cancer Institute, Aviano PN, Italy
    Anticancer Drugs 24:1069-78. 2013
    ....
  5. pmc Expression of the brain transcription factor OTX1 occurs in a subset of normal germinal-center B cells and in aggressive Non-Hodgkin Lymphoma
    Daniela Omodei
    Centro di Ingegneria Genetica CEINGE Biotecnologie Avanzate, Naples, Italy
    Am J Pathol 175:2609-17. 2009
    ..Furthermore, OTX1 expression in a subset of normal GC B cells carrying plasma cell markers suggests its possible contribution to terminal B-cell differentiation...
  6. doi request reprint Decision criteria for rational selection of homogeneous genotyping platforms for pharmacogenomics testing in clinical diagnostics
    Raffaele Di Francia
    Hematology Oncology and Stem Cell Transplantation Unit, National Cancer Institute, Fondazione G Pascale IRCCS, Naples, Italy
    Clin Chem Lab Med 48:447-59. 2010
    ..However, such methods need to fulfill the principles of analytical validation to determine their suitability to assess nucleotide polymorphisms in target genes...
  7. ncbi request reprint Nutrition in oncologic patients during antiblastic treatment
    Massimiliano Berretta
    Department of Medical Oncology, Centro di Riferimento Oncologico, National Cancer Institute, Aviano, Via Franco Gallini 2, 33081 Aviano PN, Italy
    Front Biosci (Landmark Ed) 18:120-32. 2013
    ..Based on this analysis, several nutritional proposals for cancer patients are suggested and the importance of good nutritional status in candidates for hematopoietic stem cell transplantation is highlighted...